title: Chemotherapy-induced cardiotoxicity.
abstract: Anthracycline-based chemotherapeutics have long been recognized as effective agents for treating a wide range of malignancies. However, their use is not without significant adverse cardiotoxic side effects. Strategies for prevention involve limiting free-radical production and subsequent cardiac myocyte damage. Dexrazoxane remains the most widely studied cardioprotective medication. Alternative agents may reduce cardiotoxicity but may still cause significant cardiovascular problems. The role of β-blockers and angiotensin-converting enzyme inhibitors in the treatment of heart failure is well proven. The role of these medications in the prevention and treatment of chemotherapy-induced cardiotoxicity is not well established.
authors.affiliation: University of Massachusetts Memorial Medical Center, 55 Lake Avenue North, Worcester, MA, 01655, USA.
authors.forename: Amir Y
authors.initials: AY
authors.lastname: Shaikh
authors.forename: Jeffrey A
authors.initials: JA
authors.lastname: Shih
mesh_terms: D018943:Anthracyclines / Q000009:adverse effects; D000970:Antineoplastic Agents / Q000009:adverse effects*; D006333:Heart Failure / Q000139:chemically induced* / Q000175:diagnosis / Q000517:prevention & control; D006801:Humans; D011159:Population Surveillance / Q000379:methods; D017410:Practice Guidelines as Topic
chemical_list: D018943:Anthracyclines; D000970:Antineoplastic Agents